Vitamin K2 (menaquinone-7; 360-mcg/d) for Vitamin K Deficiency

N/A

Waitlist Available

Led By Norman K Pollock, PhD

Research Sponsored by Augusta University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from baseline to 8 weeks

Summary

This trial is testing whether vitamin K supplementation can help improve vascular function in people with end-stage renal disease who are undergoing hemodialysis.

Eligible Conditions

Vitamin K Deficiency
Cardiovascular Disease
Renal Disease
Chronic Kidney Disease
Hemodialysis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline to 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline to 8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Flow-Mediated Dilation (FMD)

Pulse Wave Velocity (PWV)

Secondary study objectives

Prothrombin Time

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Vitamin K2 (360-mcg/d)Experimental Treatment1 Intervention

The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.

Group II: Placebo-ControlPlacebo Group1 Intervention

The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.

Do I qualify?Apply below to find out